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Biomarker
NIH-USA official definition: 
A characteristic that is objectively measured and evaluated as 
indicator of normal  or pathogenic biological processes or
pharmacological response to a therapeutic intervention”
Biomarker still needed for
• early detection of diseases to benefit from the potential 
therapies. 
• pharmacodynamic assessment of drug action to help guide dose 
and schedule
• selection of patients who will benefit from therapy 
(pharmacoproteomics)
impact on patient well being and financial viability of healthcare systems 
• Abnormalies in the production or function of 
the proteins are linked to health, 
environmental response and many diseases
• Protein is the main target of many therapeutic
Why Protein as Biomarker ? 
To understand how to control an 
environmenta  resp nse and or treat
a particular disease, it is necessary to 
identify t  proteins associated with 
drugs
“Proteins are two steps closer than genes to 
most biological phenomena and diseases”
Hood et al Proteomics. 2012 Sep;12(18):2773-83 
these processes and understand how 
they function.
Clinical Proteomics
Dedicated to the study of the PROTEOME 
PROFILE associated with the HEALTHY AND 
DISEASE STATE, in the search for 
DIAGNOSTIC / PROGNOSTIC / MONITORING 
BIOMARKERS or as TARGETS for the 
development of new therapeutic approaches
Proteins are complex
Genes are digital in nature with a 4-letter language, proteins are analog with a 20
letters language; genes operate in a one-dimensional world and proteins in a three-
dimensional world
Proteins is extremely complex due to: modifications by gene mutation, RNA editing,
RNA splicing, up to 400 types of covalent changes and protein processing
Proteins are dynamical, changing their 3-dimensional structures, positions in the
cell, concentrations at different cellular sites, sequences, covalent chemistries, and
interactions with other proteins and molecules of many types in response to
endogenous and exogenous stimuli;
Proteins exhibit a 106 dynamic range in tissues and a 1012 dynamic range in blood,
making quantification essential
Proteins lack the molecular complementarity of DNA and hence cannot be amplified
prior to measurement—thus, higher ultrasensitive techniques to measure and
analyze protein molecules is needed
Hood et al Proteomics. 2012 Sep;12(18):2773-83 
• Discovery-based approach
Proteomics Technology
• Targeted –based approach
Discovery -based approach
What proteins can be
detected in this sample ? 
Discovery Phase Validation/Translation Phase
Penque, Expert Rev Proteomics, 2007, 4:199-209
Torre et al, 2015. Book chapter in Methods in Molecular&Biology, in press
Discovery Proteomics approach
Data  Aquisition
2D-gel
HPLC
MALDITOFTOF
ESI-MS/MS
LC/MS/MS
Shotgun MS
Data Base Query
(GPS, Mascot, Sequest, 
GO, etc
Pathway/Network 
Analysis
Discovery-based Proteomics approach
MALDITOFTOF
Data Base Query
(Mascot, Sequest, etc
Imaging MS
protein CHIP
MALDI
SELDI-TOF
Pathway/Network 
analysis
Targeted proteomics approach
Is protein X measurable in this sample?
Shotgun proteomics
Biochemical experiments
Antibody /Affinity - based
http://www.proteinatlas.org/
21,500 Abs for 11,000 genes 
QQQ-type MS 
(SRM, SISCAPA)
MALDI-type
(MISA, iMALDI)
Mass spectrometer-based
http://www.srmatlas.org/
(170,000SRM assays for human)
Literature
The balance between scope/sensitivity/scalability of discovery and targeted proteomics.
Due to the broad-scope nature and sensitivity of discovery proteomics, the ability to 
perform a comprehensive analysis of hundreds or thousands of samples is limited. 
Conversely, targeted proteomic analysis entails the quantitation of discrete subsets of 
peptides, which allows the ability to analyze these peptides across thousands of samples 
with the highest level of sensitivity.
Quantitative Proteomics
Protein abundance and sample 
complexity are significant factors that 
affect the availability of proteins for 
mass spectrometric quantitation
R e l a t i v e
A b s o l u t e /  
Q u a n t i t a t i o nP r o t e o m i c s
Proteomics Clinical Purposes
(some examples)
Laboratório de Proteómica 
Departamento de Genética Humana
Unidade de Tecnologia & Inovação
INSA, I.P. Ricardo Jorge-Lisboa
Missões
Desenvolver uma plat forma I&D inovadora baseada na 
proteómica para valid ção, implementação de 
biomarcadores já existentes ou descoberta de novos 
Investigação Serviços Outras Actividades
Missão
biomarcadores de diagnóstico, prognóstico e 
monitorização de doenças ou como alvos a novos 
abordagens terapêuticas. 
Prestar colaboração e serviços de caracterização de 
proteínas pela proteómica 
Contribuir para o desenvolvimento da proteómica no nosso 
país (promoção/realização de cursos/estágios/conferências, 
networking) na área da proteómica
Running Projects
1. Proteomics of chronic lung diseases leading to biomarkers and 
therapeutic target discovery. FCT project POCTI/SAU-
MMO/56163/2004. PI: D Penque
2. Environmental Tobacco Smoke Exposure at Portuguese 
Restaurants, Bars and nightclubs: health effects and early 
molecular mechanisms underlying respiratory disorders. 
Research 
FCG/ACSS. PI: T Simões & D Penque.
3. MSIA technology development . PI: D Penque & V Torres
4. Obstructive sleep apnea and associated metabolic/cardiovascular 
disorders: understanding mechanisms towards early diagnosis and 
prognosis prediction.  HMSP-ICJ/0022/2011- Junior Investigator: A Feliciano, 
HPV
Chronic Lung Diseases
Cystic Fibrosis
Asthma COPD
Biormaker Discovery of Chronic Lung Diseases 
D Penque Expert Rev. Proteomics 4 (2) 2007 
 Basic mechanism responsible for 
F508del-CFTR retention in ER 
remains to be elucidated
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Gomes-Alves et al 2009, JOP, in press
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139 protein spots differentially 
expressed
125 proteins spots identified
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Several degradation associated proteins were down-regulated, while BiP and other 
UPR related proteins were found up-regulated in BHK-F508del cells under the CFTR-
“rescue” treatment at low temperature.
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Validation
by western-
blotting

Mutagenic Repair
(RXR) motifs
Low temperature
↑ BIP, mortalin, Hsp90, Hsp70
↓ proteosome (Psme2)Increase folding capacity
UPR
Unfolde protein
response
& diminish degradation
Expression Reversion of some 
proteins involved in CFTR 
maturation & trafficking   
e.g ↑ RACK1 
Promote relocation of ∆F-508-CFTR to cell surface 
Freeze in OCT
Store at -80ºC
Cryodissection
naphthalene
Challenge
Wt
F508del
CF Transgenic Mice
PALM Microscope 2000 lung epithelial cells
2D DIGE & LC/MS/MS 
(MALDI-FTICR-MS
The results suggest
the involvement of
prostaglandin and retinoic
acid metabolism in the
abnormal responses of CF 
mutant
mice to injury.
Carvalho-Oliveira et al, 2009, JPR, 8:3606-16
Carvalho-Oliveira et al, 2007, Expert Rev Mol Diag, 7:407-417 
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Serum
Dysregulated Pathways (~70 p) : 
• abnormal tissue/airway remodeling,  
protease/antiprotease imbalance, innate
immune dysfunction, 
• chronic inflammation, 
• nutritional imbalance
• P. aeruginosa colonization. 
Apolipoproteins family (VDBP, ApoA-I, and ApoB) gradually 
lower expression from non-CF to CF-carrier individuals and 
from those to CF patients, 
The enzyme NDKB was identified only in the CF, its functions 
account for ion sensor in epithelial cells, pancreatic secretion, 
neutrophil-mediated inflammation and energy production, 
highlighting its physiological significance in the context of CF.

Most enriched Pathways : 
• cell-to-cell signaling and interaction
• hematological system
• development, 
• immune response, 
• oxidative stress and 
• cytoskeleton. 
• Chorein (VPS13A) > cell
COPD
membrane deformation of RBC c 
Methemoglobin reductase
• (Cytochrome CYB5R3) > COPD 
patients may be at higher risk for 
developing methemoglobinemia.
219 proteins dysregulated in 
COPD RBCm
2012 Arnaldo 
Sampaio Award
Biomarkers for 
Obsructive Sleep Apnea is needed   
• to distinguish snoring from OSA , facilitating population 
screening and prevention of OSA-associated outcomes  
• to provide new insights into pathophysiological aspects 
of OSA that underlie the increased cardiovascular and 
metabolic risk in general population 
PROTEOMICS
OSA Patients
& Controls
Clinical Evaluation
& PSG-Laboratory
Study
Clinical/Sample  Database
Biobanking
Sample Preparation for 
PROTEOMICS
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Analysis
CANDITATES BIOMARKERS OF OSA 
VERIFICATION   PHASE
Feliciano et al Sleep Medicine 2015
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Summary
Proteomics can provide:
• New insights into the poorly-understood
pathogenetic processes of diseases.
• New biomarkers for diagnosis & prognosis
• New targets for development of novel
therapeutic approaches.
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